CD4 and neoplasm: We observed significant enriched of CD8+CD45+ and CD4+CD45+ T cells in DR5 agonist‐treated tumors regardless of ROCK1i and avelumab co‐treatments (Fig 6A and B, Appendix S10, n = 6–20 tumor‐bearing animals, three separate experiments).